Related Experiment Videos
Microwave coagulation therapy for unresectable hepatocellular carcinoma
Masanori Aramaki1, Katsunori Kawano, Tsuyoshi Ohno
1Department of Surgery I, Oita Medical University, Hasama, Oita, Japan.
Hepato-Gastroenterology
|November 10, 2004
Summary
Microwave coagulation therapy (MCT) offers an alternative for unresectable hepatocellular carcinoma. While intrahepatic recurrences are common, preserved liver function allows for effective locoregional therapies, improving survival rates.
Area of Science:
- Hepatobiliary Surgery
- Oncology
- Minimally Invasive Procedures
Background:
- Surgical resection is not always feasible for hepatocellular carcinoma (HCC).
- Microwave coagulation therapy (MCT) presents an alternative treatment option.
- Evaluation of MCT efficacy in unresectable HCC is crucial.
Purpose of the Study:
- To assess the efficacy of microwave coagulation therapy (MCT) for unresectable hepatocellular carcinoma (HCC).
- To evaluate patient outcomes and survival rates following MCT.
- To analyze the impact of MCT on liver function in HCC patients.
Main Methods:
- Twenty-four patients with unresectable HCC underwent MCT via laparotomy, laparoscopy, or thoracoscopy.
- Treatment involved single or multiple nodules ranging from 10 to 50 mm.
- Liver function and patient outcomes were monitored post-MCT and for recurrence.
Main Results:
- Two postoperative deaths occurred; other patients recovered without hepatic dysfunction.
- Liver function remained stable before initial MCT and before recurrence treatment.
- The 3-year cancer-free survival rate was 9.9%, and the 3-year cumulative survival rate was 83.9%.
Conclusions:
- MCT is indicated for HCC patients with advanced liver cirrhosis, leading to frequent intrahepatic recurrences.
- Preserved liver function post-MCT enables selection of locoregional therapies for recurrences.
- This approach can significantly improve patient survival rates in HCC.